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Abstract
The implementation of whole-exome sequencing in clinical diagnostics has generated a need for functional evaluation of genetic
variants. In the field of inborn errors of metabolism (IEM), a diverse spectrum of targeted biochemical assays is employed to
analyze a limited amount of metabolites. We now present a single-platform, high-resolution liquid chromatography quadrupole
time of flight (LC-QTOF) method that can be applied for holistic metabolic profiling in plasma of individual IEM-suspected
patients. This method, which we termed Bnext-generation metabolic screening^ (NGMS), can detect >10,000 features in each
sample. In the NGMS workflow, features identified in patient and control samples are aligned using the Bvarious forms of
chromatography mass spectrometry (XCMS)^ software package. Subsequently, all features are annotated using the Human
Metabolome Database, and statistical testing is performed to identify significantly perturbed metabolite concentrations in a
patient sample compared with controls. We propose three main modalities to analyze complex, untargeted metabolomics data.
First, a targeted evaluation can be done based on identified genetic variants of uncertain significance in metabolic pathways.
Second, we developed a panel of IEM-related metabolites to filter untargeted metabolomics data. Based on this IEM-panel
approach, we provided the correct diagnosis for 42 of 46 IEMs. As a last modality, metabolomics data can be analyzed in an
untargeted setting, which we term Bopen the metabolome^ analysis. This approach identifies potential novel biomarkers in
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known IEMs and leads to identification of biomarkers for as yet unknown IEMs. We are convinced that NGMS is the way
forward in laboratory diagnostics of IEMs.
Keywords Metabolomics . Biomarkers . High-resolution . QTOF . Mass spectrometry . Innovative laboratory diagnostics .
Inborn errors of metabolism . Canavan disease . Xanthinuria
Introduction
The number of known inborn errors of metabolism (IEMs) has
grown substantially in recent decades, amounting to ~1000
individual conditions, with accumulative incidence of
~1:1000 newborns. For a selection of treatable IEMs, routine
newborn screening (NBS) has been implemented for early
diagnosis. However, most IEMs are not covered in NBS, and
for those conditions, diagnostic profiling in the metabolic lab-
oratory is indispensable to reach a correct diagnosis for an
individual patient. The current diagnostic toolbox for IEM
screening comprises a panel of targeted analyses based on a
variety of analytical techniques, including gas chromatogra-
phy mass spectroscopy (GC-MS), liquid chromatography tan-
dem mass spectroscopy (LC-MS-MS), and ion-exchange
chromatography. The metabolic laboratory therefore must
maintain a substantial number of different analyzers and use
laborious manual methods. Due to time and logistic restraints,
it is not feasible to apply all possible methods for IEM screen-
ing to each individual patient. Therefore, in current practice,
clinical symptomatology is leading in the selection of specific
analyses for an individual patient. However, this strategy
heavily relies on the completeness of clinical information pro-
vided to the metabolic laboratory and therefore holds the risk
of false-negatives if a metabolic test has not been performed
due to incomplete description of patient symptoms.
Additionally, the discovery of novel metabolic defects is likely
hampered by investigating only a limited selection of known
metabolic pathways. Thus, there is a demand for a holistic
approach to metabolite analysis in IEM screening, and tech-
nologies to fulfill this unmet clinical need are emerging: ad-
vanced, high-resolution mass spectrometry (MS) enable
untargeted investigation of the metabolite profile, i.e. a holistic
overview of small molecules with a mass <1500 Da in a bio-
logical system at a certain time point. In analogy to other
holistic B–omics^ technologies, it is referred to as
Bmetabolomics^ (Nicholson et al. 1999). Untargeted metabo-
lomics is widely applied to generate fundamental mechanistic
insights in research fields ranging from environmental science,
to toxicology, to human diseases in which cancer, cardiovas-
cular disease, and diabetes have been main subjects (Johnson
et al. 2016). In IEMs, untargeted metabolomics is gradually
emerging (Tebani et al. 2016). In the 1990s, application of
high-resolution proton nuclear magnetic resonance (NMR)
for diagnosing IEMs was developed in our laboratory, which
led to the identification of several new IEMs (Iles et al. 1995;
Wevers et al. 1995). However, NMR spectroscopy did not
evolve as a common IEM screening technique, likely because
of the financial constraints and relatively low sensitivity
(Emwas et al. 2013). High-resolution liquid chromatography
(LC)-MS-based metabolomics can overcome this sensitivity
problem, as the detection limit is in the low nanomolar range,
compared with the low micromolar range of NMR. In 2007,
Wikoff and co-workers evaluated the potential of untargeted
LC-time-of-flight (TOF) MS for classical methylmalonic
aciduria (MMA (mut0), OMIM #251000) and propionic
aciduria (PA, OMIM #606054). Their proof-of-concept study
identified known biomarkers and showed that an untargeted
approach increases the possibility of identifying new bio-
markers in known disorders (Wikoff et al. 2007). A similar
untargeted metabolomics study on patients and obligate het-
erozygotes for isovaleryl-CoA dehydrogenase deficiency
(IVA, OMIM #243500) demonstrated a clear metabolic dis-
crimination between these groups and identified different met-
abolic profiles in treated and untreated IVA patients (Dercksen
et al. 2013). Also, untargeted LC-MS metabolomics in urine
distinguished types I and II xanthinuria profiles (Peretz et al.
2012). Another example was the promising evaluation of an
untargeted high-resolution MS method for analysis of dried
blood spot (DBS) samples for NBS on phenylketonuria
(PKU, OMIM #261600) and medium-chain acyl-CoA dehy-
drogenase deficiency (MCADD, OMIM #201450) (Denes
et al. 2012). Additionally, several applications of untargeted
metabolomics to other IEMs have been published, including
respiratory-chain defects, mucopolysaccharidosis type I, and
infantile cerebellar–retinal degeneration associated with mito-
chondrial aconitase (ACO2) deficiency (Smuts et al. 2013;
Venter et al. 2015; Tebani et al. 2017; Abela et al. 2017).
In all IEM metabolomics studies referred to above,
untargeted metabolomics was applied to predefined patient
groups, and statistical analysis was performed by comparing
control versus patient groups to identify disease-specific bio-
markers. However, the application of high-resolution metabo-
lomics in routine diagnostic screening for IEMs requires meth-
odology that can robustly profile individual patients without
prior knowledge of the diagnosis. In this journal, Miller et al.
previously reported an untargeted metabolomics approach for
screening individual patients for IEMs (Miller et al. 2015).
Even though that study showed promising results, it involved
a dual-platform approach, and resolution was not optimal, as
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the amount of individual metabolites identified was not on a
Bbig-data^ level, and key IEM biomarkers were missed (e.g.,
guanidinoacetate, methylmalonate, tetradecenoylcarnitine,
and tetradecadienoylcarnitine). High-resolution metabolite de-
tection is indispensable to fully exploit the possibilities of
metabolomic approaches for both diagnosing known IEMs
and identifying novel diseases and/or biomarkers in individual
patients.
We present a single-platform, untargeted, high-
resolution LC quadrupole time-of-flight (QTOF) metabol-
ic profiling method that can be applied in the diagnostic
screening for IEMs in individual patients, which we
named next-generation metabolic screening (NGMS). We
clinically validated the diagnostic performance of our
NGMS strategy through analysis of plasma samples from
patients with 46 distinct IEMs. Using our analytical and
semiautomated data-processing approach, we detected
>10,000 features—i.e., signals with a specific mass-to-
charge ratio, intensity, and retention time—in a plasma
sample of an individual patient. To extract clinically rele-
vant metabolite/feature information on IEM diagnosis, we
selected features that significantly different between indi-
vidual patients and controls and cross-referenced them to
a panel of 340 known IEM-related metabolites. As a sub-
sequent step, the full metabolomic profile is available for
exploratory untargeted analysis. In this study, we focus on
results of the clinical validation study and show examples
of the added clinical value of NGMS-based diagnostics in
IEMs.
Methods
Sample collection
For a spectrum of 46 distinct IEMs (Table 1), plasma samples
were available. Heparin blood samples of these patients was
drawn for routine metabolic screening or follow-up in our
laboratory. Due to the retrospective nature of this study, no
specific collection protocol was followed regarding time of
specimen collection and dietary status. All patients (or their
guardians) approved the possible use of their remaining sam-
ples for method validation purposes, in agreement with insti-
tutional and national legislation. IEM diagnosis was con-
firmed by enzymatic and genetic testing, when appropriate,
according to available guidelines or expert opinion of the lab-
oratory specialist or attending clinician. Control samples were
obtained from remaining material from the general clinical
chemistry diagnostic laboratory, again with patient approval.
All samples were stored in a digital-alarm-controlled freezer at
−20 °C before analysis for a period ranging from 3 years to 2
months. See Supplemental Table 1 for complete IEM diagnos-
tic panel used for targeted evaluation of NGMS data.
Sample preparation
Frozen human heparin-anticoagulated plasma was thawed at
4 °C and mixed by vortexing. An aliquot of 100 μl of plasma
was transferred into a 1.5-ml polypropylene microcentrifuge
tube. Then, 400 μl ice-cold methanol/ethanol (50:50 vol/vol)
containing five internal standards (IS) [caffeine-d3 0.88 μmol/
L, hippuric-d5 acid 0.22μmol/L, nicotinic-d4 acid 0.88 μmol/
L, octanoyl-L-carnitine-d3 0.22 μmol/L, L-phenyl-d5-alanine
0.44 μmol/L (all from C/D/N Isotopes, Pointe-Claire,
Canada)] was added to each plasma aliquot. Samples were
thoroughly mixed on a vortex mixer for 30 s, incubated at
4 °C for 20 min, and centrifuged at 18,600 g for 15 min at
4 °C. An aliquot of 350 μl of the supernatant was transferred
into a 1.5-ml polypropylene microcentrifuge tube. Samples
were dried in a centrifugal vacuum evaporator (Eppendorf,
Hamburg, Germany) at room temperature, reconstituted in
100 μl of water containing 0.1% (vol/vol) formic acid,
vortexed for 15 s, and centrifuged at 18,600 g for 15 min at
room temperature. An aliquot of 90 μl was transferred into
250 -μl polypropylene autosampler vials. These samples were
either placed in an autosampler at 4 °C for direct analysis or
stored at −80 °C. Stored samples were thawed at room tem-
perature and centrifuged at 18,600 g for 15 min at room tem-
perature before analysis.
UHPLC-QTOF-MS analysis
An Agilent (Santa Clara, CA, USA) 1290 ultra-high-
performance (UHP) LC system coupled to an Agilent 6540
or 6545 QTOF mass spectrometer equipped with a dual
electrospray ionization (ESI) source was used for untargeted
analysis of plasma samples. Each sample was run in duplicate
in both positive and negative ionization modes. A 2.0 -μl
aliquot of extracted plasma sample was injected onto an
Acquity HSS T3 (C18, 2.1 × 100 mm, 1.8 μm) column
(Waters, Milford, MA, USA) operating at 40 °C.
Chromatographic separations were performed by applying a
binary mobile phase system. For analyses carried out in the
positive ESI mode, mobile phase A consisted of water con-
taining 0.1% (vol/vol) formic acid and mobile phase B was
water/methanol (1:99 vol/vol) containing 0.1% (vol/vol)
formic acid. For analyses performed in the negative ESI mode,
mobile phase A consisted of water containing 10 mmol/L
acetic acid and mobile phase B was water/methanol (1:99
vol/vol) containing 10 mmol/L acetic acid. The flow rate
was 0.4 ml/min; for gradient elution, an isocratic period of
1 min at 1% B followed by a linear gradient from 1% B to
100% B over 15 min was applied. The final composition of
100% B was held constant for 4 min followed, by a return to
1% B in 1 min and an equilibration at 1% B for 4 min.
QTOFmass spectrometer was operated in positive ion mode
with a capillary voltage of 2000 V, a nebulizer gas pressure of
J Inherit Metab Dis (2018) 41:337–353 339
Table 1 Overview of next-generation metabolic screening (NGMS) results for 46 distinct inborn errors of metabolism (IEMs). For each IEM,
indicative metabolite alterations are shown. Please refer to Supplemental Table 1 for the complete IEM diagnostic panel used for targeted evaluation
of NGMS data
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60 psi, a drying gas temperature of 275 °C, and a drying gas
flow rate of 11 L/min. For the negative mode, these character-
istics were 4000 V, 35 psi, 250 °C, and 12 L/min. The mass
spectrometer was operated in the extended dynamic range
mode. Mass spectral data were acquired in the profile mode
using a scan range of 60–1000 m/z with a scan time of 0.33 s.
Each analytical batch was composed of control plasma
samples, IEM patient plasma samples, quality control (QC)
plasma pool samples, a performance-check solution (PC),
and a solution of IS. An analytical run consisted of a maximum
of 150 samples. The set of control plasma samples was opti-
mized for each run to mimic age- and gender variation in
patient samples analyzed in that run. Minimum amount of
control plasma samples in a single run was 15. To correct for
possible run-order influence on signal intensities, duplicates of
patient samples were analyzed in antiparallel run order, mean-
ing that duplicates of the first patient sample were analyzed on
first and last position in the analytical run, while duplicates of
the last patient sample were analyzed in the two middle
positions of the run. Also, in some runs, solutions containing
a combination of reference standard compounds were subject-
ed to NGMS analysis to establish retention time for identifi-
cation purposes (see Supplemental Table 1 for specification of
which reference standards were analyzed). These standards
were acquired through several suppliers (Sigma,
Brunschwig, Merck, J.T. Baker Chemical, Fluka Chemika,
Cambridge Isotope Laboratories Inc., BDH, and Aldrich).
The QC plasma pool consisted of a mixture of 800 plasma
samples collected from leftover material from the clinical
chemistry laboratory. Samples were selected from 50% male
and 50% female patients varying in age between 1 month and
90 years; 50 μl of each individual sample was used to prepare
the pool. The QC plasma pool was thoroughly mixed, and
aliquots stored at −80 °C. The PC solution for the positive
ESI mode was adenosine, caffeine, creatine, dimetridazole,
epitestosterone, 2-methylbutyrylcarnitine, nicotinic acid,
propionylcarnitine, stearoylcarnitine, L-tryptophan, and L-
tyrosine in mobile phase A. Concentration of each compound
Metabolite-related features were found in positive ([M +H]+ and [M +Na]+ adducts) and negative ([M −H]+ and [M +Cl]- adducts) ionization modes
Arrows indicate increased (↑) or decreased (↓) intensity of the indicated feature in the patient sample compared with controls, one arrow: fold change 1–
10, two arrows: fold change 10–100, three arrows: fold change >100. The column labeled ID indicates whether identity of a specific metabolite was
confirmed by a model compound/reference standard (1), measurement of corresponding m/z in ≥2 diagnostic samples (2), or measurement of a
corresponding m/z in a single diagnostic sample (0), NA indicates that the specific data was not available
a Not selected by standard statistical testing, corrected P value >0.05
bObserved and abnormal in raw data but not observed in aligned data
c Not observed in raw data
d Identification based on 13 C–isotope of feature due to saturation of 12 C–isotope peak
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was 0.1 μg/ml. The PC solution for the negative ESI mode
was 2-amino − 3-methylbenzoic acid, trans-cinnamic acid,
h i p p u r i c a c i d , 4 - h y d r o x y b e n z o i c a c i d , 1 2 -
hydroxyoctadecanoic acid, nicotinic acid, sebacic acid, L-tryp-
tophan, L-tyrosine, and xanthine in mobile phase A. The con-
centration of each compound was 0.5 μg/ml.
Control and patient plasma samples were analyzed in du-
plicate. Eight random control plasma samples were injected at
the start of each analytical batch to condition the analytical
platform. The PC solution and the QC plasma pool were
injected following 15–20 control and/or patient plasma sam-
ples. Data analysis of the PC solution and the QC plasma pool
were used to monitor the performance of the analytical plat-
form by calculating the technical precision within each analyt-
ical batch (within-run precision) for retention time (RT) and
MS intensity. Precision data was based on data of all standards
present in the PC solution, while for the QC plasma pool, a
representative selection of endogenous metabolites was
assessed: for the positive mode, piperidone, pyroglutamic ac-
id, creatine, hypoxanthine, carnitine, uric acid, arginine,
hippuric acid, homocitrulline, caffeine, propionyl-carnitine,
sulfamethoxazol, hexanoyl-carnitine, octanoyl-carnitine, gua-
nosine, and C18:1- and C18:2-lysophosphatidylcholine were
evaluated, while in the negativemode, selection of metabolites
included 2- and 3-hydroxy-butanoic acid, oxovaleric acid, 3-
hydroxy-isovaleric acid, 3- and 4-methyl-2-oxovaleric acid,
N-acetylalanine, xanthine, phenylalanine, phenyllactic acid,
uric acid, hippuric acid, pyridoxic acid, hydroxyl-hippuric ac-
id, sebacic acid, tryptophan, N-phenylacetylglutamine, ino-
sine, testosterone sulphate, taurocholinic acid, and C16:0-,
C18:0-, C18:2-, and C20:4-lysophosphatidylcholine.
Data processing and statistics
The output files of the QTOF runs were aligned using the
open-access software package various forms of chroma-
tography mass spectrometry (XCMS) in single job modus.
Following alignment and feature extraction, features were
annotated against the Human Metabolome Database
[HMDB] (Wishart et al. 2007) for putative metabolite
identification. For all features, two-sided t tests were per-
formed to identify significantly altered features between
an individual patient and controls. Because of the large
number of features identified in an individual patient
(~10,000), the Bonferroni procedure (Dunn 1961) was
used to correct for multiple testing to prevent false-
positive selections, i.e., features incorrectly marked as sig-
nificantly different in a patient. Two types of t tests were
applied to compare the intensity of each feature present in
an individual patient sample to the intensities observed in
control samples. In the first test, replicate measurements
of each observation (patient or control) were first aver-
aged. Subsequently, for each feature present in an
individual patient sample, the average intensity of its rep-
licate measurements was compared with the mean inten-
sity of that feature in all control samples. In the second
test, the single-patient measurement of a specific feature
that was most similar to controls (i.e., one of two repli-
cates) was used for comparison with means of control
plasma samples. The Bonferroni procedure was applied
separately to the output of the two types of t tests sepa-
rately. Only peaks marked as significantly different by
both approaches after Bonferroni correction (P value
<0.05) were retained for further analysis. This combina-
tion of tests, rather than using a single t test, was
employed to control for false positives in case of technical
variability of the UHPLC-QTOF setup.
Data interpretation
To extract relevant diagnostic information from the
untargeted metabolomics data, we developed an in-house
IEM panel that consisted of 340 IEM-related metabolites,
which was used to filter the total list of identified features.
Based on the exact mass of a metabolite, hypothetical
masses of proton, sodium, and chlorine adducts were cal-
culated and included in this IEM panel, as well as hypo-
thetical masses for deprotonated ions. Additionally, hypo-
thetical masses of C isotopes (Tebani et al. 2017) were
calculated and incorporated. Information on established
retention times of reference standards, which were avail-
able for 222 of the 340 panel metabolites (65%), was
included in the IEM panel to allow for high confidence
identification according to guidelines of the Metabolomics
Standards Initiative (Sumner et al. 2007). For metabolites
unavailable as reference standard, evidence for identifica-
tion was gathered from biological reference samples (pa-
tients with established IEM diagnosis, for 36/340 panel
metabolites, 11%), isotope ratios, specific in source frag-
mentation patterns, HMDB classification (endogenous
versus drug, food, or microbial origin of metabolite), or
Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Kanehisa et al. 2017) information on common metabolic
pathways. Significantly different features were extracted
based on the t test procedure described above, a ppm
deviation of <5 for mass accuracy, and—when a reference
standard was available—a relative retention time differ-
ence between this reference standard and the metabolite
in the biological sample of <10%. Features that withstood
this filtering procedure were then prioritized based on
their intensity and on the fold difference in intensity be-
tween mean intensity of the patient feature and controls
(fold change). Intensities of a specific feature, comparing
an individual patient to all controls analyzed within one
analytical run, were visualized in barplots using
Unscrambler software (Camo Software, Oslo, Norway).
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Results
Analytical performance
Samples were measured over 60 analytical series in which
both positive and negativeMS ionizationmodes were applied.
The series were performed from November 2013 to
May 2017. In July 2016, an upgrade of the QTOF system
was implemented, which involved a switch from the Agilent
6540 to the Agilent 6545; the same UHPLC system was used
with both. A selection of IEM patient samples, based on avail-
ability, was rerun on the upgraded setup as part of its valida-
tion procedure. In total, 20 of the 60 analytical runs described
here were performed on the Agilent 6545 setup. There was no
significant difference in the identification of clinically relevant
metabolites between systems, confirming the reliability and
robustness of the methodology.
In the validation, the Agilent 6545 showed increased
sensitivity with a factor up to ten for different metabolites,
as was expected from the manufacturer’s specifications.
For other performance characteristics, the Agilent 6545
was either comparable with or superior to the Agilent
6540; therefore, only specifications of the Agilent 6545
analytical performance are further detailed here. Stability
of the analytical platform was evaluated based on within-
run precision data of the PC samples. For standards with
retention times >2 min, a coefficient of variation (CV) of
≤0.5% for retention time was accepted, while for retention
times <2 min, this limit was set to ≤1%. Results of within-
run precision of retention times always fulfilled these
criteria and in practice rarely exceeded 0.5%, as for reten-
tion times <2 min. For MS signal intensities detected for
the standards, a maximum within-run CV of 15% was
allowed, adhering to recommendations from the literature
for performance (Dunn et al. 2011). The actual analytical
within-run CV for intensity was lower than the target lim-
it—mostly <10%. For mass accuracy, a maximal error of
5 ppm was accepted, but in practice, this rarely exceeded
3 ppm. Regarding between-run precision, a maximum CV
of 1% was found for retention times >2 min and 2% for
retention times <2 min. For MS signal intensities, the me-
dian of between-run CVs was 23% in the negative mode
and 30% in the positive mode.
A plasma pool QC sample was included several times in
each run to gain insight into within-run precision of retention
time and intensity for a selection of endogenous metabolites in
a clinically relevant matrix. For both positive and negative
ionization modes, a specific combination of metabolites was
selected for evaluation (see BMethods^ section). Within-run
precision performance criteria were equal to those for the PC
sample, with the exception of the CV accepted for the MS
signal intensity, which was 20%. Regarding between-run pre-
cision for the plasma pool QC sample, comparable
performance with the PC sample was reached. CVs for reten-
tion time were <2%, while median CV for intensity was 16%
for the negative and 31% for the positive mode.
To evaluate the correlation of semiquantitative NGMS results
to the exact molar concentrations obtained through conventional
techniques, we compared them for a selection of metabolites:
phenylalanine, leucine, free carnitine, octanoylcarnitine,
decenoylcarnitine, and 3-hydroxyisovalerylcarnitine. For most
samples, conventional carnitine and amino acid analysis was
performed, enabling this comparison. Linear regression analysis
showed good correlation between intensities measured in
NGMS and actual concentration, with, for example R2 values
>0.95 for octanoyl-carnitine, 3-hydroxy-isovaleric carnitine,
and phenylalanine. For free carnitine, correlation was least op-
timal, with an R2 of 0.5651 (Supplemental Fig. 1).
NGMS-based screening of IEMs in individual patients
We applied our NGMS technology to delineate plasma
metabolomic profiles of 46 distinct IEMs (Table 1). All pa-
tients were on diagnosis-specific treatment following avail-
able guidelines or based on expert opinion of attending clini-
cians. Because of treatment, biochemical abnormalities were
expected to be less pronounced compared with those detected
in samples of untreated patients. In each individual plasma
sample, >10,000 features could be detected. Due to the high
level of complexity of data generated through this untargeted
NGMS methodology, we searched for an application feasible
for future implementation in routine patient diagnostics. In
analogy to routine diagnostic analysis of big data generated
from next-generation (exome) sequencing strategies through
disease-specific filters, we developed an IEMmetabolite panel
containing 340 clinically relevant metabolites known to be
either diagnostic or associated with common therapeutic inter-
ventions for IEMs (Supplemental Table 1) as a first filtering
step to reduce data complexity and extract relevant diagnostic
information. Through a semi-automated pipeline developed
in-house, all features detected in a plasma sample were com-
pared between an individual patient and controls. Bonferroni-
corrected P values were calculated for statistical significance
of each feature. Open-access metabolite information from the
HMDB was integrated for metabolite annotation (see
BMethods^ section). Only significantly different features be-
tween a patient and controls were evaluated and reported.
Based on chemical characteristics of the metabolite, different
adducts were preferentially formed (see Table 1). Following
this approach, we identified key diagnostic metabolites in 42
of 46 (91%) IEMs tested (see Fig. 1) to visualize results in
barplots of feature intensity for a selection of IEMs. Among
those IEMs were several organic acidurias, for which the rel-
evant urinary biomarkers could readily be detected in plasma
using the NGMS approach. In our set of 46 IEMs tested, four
diagnoses remained undetected by the standard NGMS
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workflow: guanidinoacetate methyltransferase (GAMT) defi-
ciency, argininosuccinic aciduria, dimethylglycine dehydro-
genase deficiency, and lysinuric protein intolerance. In the
first three of these diseases, peaks could be detected in raw
data files at the expected m/z and retention time for the rele-
vant metabolites guanidinoacetate, argininosuccinic acid, and
dimethylglycine (Supplemental Fig. 2). However, these fea-
tures were not present in the XCMS output file, indicating that
they were lost in the alignment procedure. For lysinuric pro-
tein intolerance, a negative fold change (−3.2×) for lysine was
observed in raw data but was rejected in our statistical selec-
tion (corrected P value >0.05).
For saturated peaks, feature annotation can fail if the re-
quired level of mass accuracy cannot be reached. Saturation
was found for phenylalanine in phenylketonuria patients and
for 3-methyl-crotonylglycine in 3-methyl-crotonyl-CoA car-
boxylase (3-MCC) deficiency. To overcome this issue, we
used the unsaturated peak of the naturally occurring 13C iso-
tope for identification. This approach led to successful identi-
fication of phenylalanine and 3-methyl-crotonylglycine as be-
ing significantly increased in relevant patient samples, despite
saturation of the 12C signal. To prevent any possible false
negatives due to peak saturation of the respective biomarker,
we included the calculated hypothetical masses of the 13C
isotopes of all metabolites in our IEM reference panel.
To test the robustness of our NGMS approach, we applied
this method to a batch of ten samples (hyperprolinemia type II,
hyperlysinemia type I, maple syrup urine disease (MSUD),
aminoacylase I deficiency, and 3-hydroxy−3-methylglutaryl-
CoA lyase deficiency; two samples for each disease) in a
blinded fashion, meaning that both the technician and the lab-
oratory specialist interpreting the metabolomic profile had no
prior knowledge of the diseases selected. Through our NGMS
pipeline, all five disorders could be unequivocally diagnosed
through the expected metabolic perturbations, as stated in
Table 1 (data for blinded study are not shown separately).
Added clinical value of NGMS-based diagnostics
in IEMs
Having shown that NGMS is capable of diagnosing a broad
spectrum of known IEMs, we now highlight novel applications
of this methodology that provide additional clinical value com-
pared with conventional biochemical IEM screening. We pres-
ent a multistep NGMSworkflow in which three main pillars for
data analysis can be defined (Fig. 2): besides targeted IEM
panel analysis, whole-exome sequencing-directed analysis and
untargeted analysis (open the metabolome) can be performed.
We illustrate these pillars through a selection of cases.
Targeted IEM panel analysis: increased specificity
for diagnosis of xanthinuria types I and II through plasma
NGMS analysis
Identifying and validating diagnostic biomarkers are key objec-
tives to support IEM screening diagnostics. In 2012, Peretz et al.
reported novel urinary biomarkers that can distinguish between
xanthinuria type I [isolated xanthine dehydrogenase (XDH) de-
ficiency] and type II [combined deficiency ofXDH and aldehyde
oxidase (AO)] (Peretz et al. 2012). These specific markers for
type II are a result of AO deficiency in several metabolic path-
ways: increased N-methylnicotinamide and decreased N-
methylpyridone carboxamides from the nicotinamide degrada-
tion pathway; decreased hydantoin propionic acid from histidine
metabolism; decreased N1-methyl-8-oxoguanine from nucleic
acid metabolism; and decreased pyrrolidine-2-one from
Octanoylcarnitine 3-Hydroxyisovaleric acid
Ornithine
a b
c dSuccinyladenosine
Fig. 1 Feature intensity for a selection of inborn errors of metabolism
(IEMs.) In all panels, boxplots show feature intensity distribution in
control plasma samples, the X-axis represents feature peak area in
arbitrary units. The black box represents the middle 50% of the
distribution in control plasma samples; white square represents median of
this distribution; left and right whiskers represent lowest and highest value
measured in controls. Patient values are shown in red. a Medium-chain
acyl-CoA dehydrogenase deficiency: data shown for octanoylcarnitine,
m/z 288.2179 ([M+H] + adduct, retention time (RT) 9.60 min), which is
significantly increased in the patient sample compared with 27 controls
(fold change 52.8). b 3-Hydroxy-3-methylglutaryl CoA-lyase deficiency:
data shown for 3-hydroxyisovaleric acid, m/z 117.0557 ([M −H] − adduct,
RT 3.43 min), which is significantly increased in the patient sample com-
pared with 28 controls (fold change 28.1). c Adenylosuccinate lyase defi-
ciency: data shown for succinyladenosine, m/z 384;1144 ([M +H]+ adduct,
RT 4.71 min), which is significantly increased in the patient sample com-
pared with 29 controls (fold change 264.6). d Ornithine amino transferase
deficiency: data shown for ornithine, m/z 133.09714 ([M +H]+ adduct, RT
0.49 min), which is significantly increased in three patient samples com-
pared with 27 controls (mean fold change 7.1)
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spermidine degradation. Using our NGMS strategy, we evaluat-
ed these AO-specific urinary markers in plasma of type II pa-
tients and replicated urinary findings in plasma, in which we
found even more pronounced fold changes between patient and
controls than described by Peretz et al. (Fig. 3). These data show
that our NGMS methodology is able to specifically diagnose
xanthinuria type II in plasma. Remarkably, in contrast to the
results of Peretz et al., we confirmed the involvement of AO in
vitamin B6 metabolism, as we found a significantly decreased
concentration of pyridoxate in patients compared with controls.
Whole-exome sequencing (WES)-directed evaluation
of NGMS data
For variants of uncertain significance (VUS) identified in
metabolism-related genes, NGMS can provide a functional
counterpart to further delineate the possible pathogenic nature
of the genetic alteration. As an example, in a 1-year-old patient
with developmental delay, epilepsy, and hearing loss, a homo-
zygous missense variant of uncertain significance [c.509 T >C;
p.(Ile170Thr)] was identified in ASPA (NM_001128085.1)
through whole-exome sequencing. At the time of ASPA
Ile170Thr variant identification in our patient, this variant had
not been described before, and its pathogenicity was considered
to be unclear based on modest conservation of the mutated
amino acid and presence of the variant in the heterozygous state
in control cohorts (0.10% in GoNL and 0.031% in The Exome
Aggregation Consortium). Mutations in ASPA are associated
with Canavan disease (OMIM 271900), a leukodystrophy that
presents in the first year of life with delayed psychomotor de-
velopment, hypotonia, macrocephaly, and epilepsy after an ini-
tially normal development. In the analysis of organic acids in
urine of this patient, a mildly increased excretion of the
Canavan-linked metabolite N-acetylaspartate was found
(~200 μmol/mmol creatinine); however, in other known
Canavan patients, a more pronounced excretion of N-acetyl as-
partate (>1000 μmol/mmol creatinine) is usually detected.
Therefore, organic acid analysis in urine did not confirm nor
exclude the diagnosis. In the Canavan patient included in our
NGMS clinical validation, a significantly increased concentra-
tion of N-acetylaspartate could readily be detected in plasma
(Table 1, IEM 12). Following NGMS analysis, for the patient
with the ASPA Ile170Thr VUS, we found N-acetylaspartate in
plasma was in the high–normal range but not significantly al-
tered comparedwith controls (Fig. 4a, b). Therefore, we propose
that the ASPA Ile170Thr VUS likely retains residual enzymatic
activity, making it nonpathogenic in homozygous form.
Untargeted open the metabolome analysis
In the pillar of untargeted NGMS analysis, two modalities can
be defined: identification of novel biomarkers in known IEMs,
and identification of as yet unknown IEMs. As an example of
the first modality, untargeted analysis of the known IEM
histidinemia (OMIM# 235800) showed a significantly increased
concentration of a feature with an m/z of 157.0768 and RT of
0.71 min in positive ionization mode (Fig. 4e). According to
HMDB annotation, this mass could correspond to the protonat-
ed adduct of imidazole lactic acid (HMDB02320). According to
information in KEGG, imidazole lactic acid can be formed
nonenzymatically from imidazole pyruvate, which is in its turn
formed from histidine by histidine transaminase. Accumulation
of histidine is therefore likely to lead to an increased concentra-
tion of imidazole lactic acid. This metabolic perturbation has not
been reported previously in histidinemia but is now putatively
detected by our NGMS approach, even though definite identifi-
cation will require further study of a model compound or or-
thogonal methods, such as NMR, MS/MS, or infrared spectros-
copy. Also, we performed open the metabolome analysis in
seven PKU patients under treatment. It was apparent that, be-
sides previously described PKU biomarkers, two unknown fea-
tures with m/z 328.1391 (RT 4.01 min) and 424.1716 (RT
6.38 min) were identified as significantly increased in most pa-
tients. Very recently, these features were identified using multi-
stage fragmentation MS as a phenylalanine–hexose conjugate
and a glutamine-glutamine-phenylalanine tripeptide, respectively
(Vaclavik et al. 2017). These novel markers showed higher
interpatient variation compared with the regular marker,
Fig. 2 Next-generation metabolic screening (NGMS) multistep
workflow
J Inherit Metab Dis (2018) 41:337–353 347
phenylalanine, making them interesting candidates to further
explore predictive value for patient clinical status—for example,
for the effectiveness of dietary intervention. The second open the
metabolome modality encompasses identifying as-yet unknown
IEMs through novel biomarkers. Untargeted data analysis can
identify novel markers that, in combination with information
from KEGG and/or WES analysis, can be linked to disease.
An example of this was the identification of a significantly in-
creased feature in body fluids of patients with severe develop-
mental delay and dysmorphism, which could be annotated as N-
acetylmannosamine. This finding led to the novel diagnosis ofN-
acetylneuraminic acid phosphate synthase (NANS) deficiency,
as was previously reported by us (van Karnebeek et al. 2016).
Discussion
We here present NGMS as a single-platform, untargeted, high-
resolution LC-QTOF, metabolomic profiling method that can
be applied in the diagnostic screening for IEMs in
individual patients. We were able to show the capability
of the NGMS setup for the diagnosis of 46 individual
IEMs through relevant biomarkers. The strength of our
NGMS workflow is that, even though targeted screening
for known IEM-associated metabolites is performed as a first
step, untargeted metabolomics data is available to undergo a
subsequent round of untargeted data analysis, which we term
Bopen the metabolome^. We foresee a workflow in which
unclassifiable perturbations in IEM panel analysis or negative
results for highly suspect patients will be followed up by
untargeted data analysis. Also, patients already diagnosed
with an IEM but with an atypical response to treatment or
disease course are relevant candidates for untargeted NGMS
analysis. This stepwise strategy will allow for the identifica-
tion of novel biomarkers and diseases while containing man-
ageability of NGMS data for routine IEM diagnostics. The
stepwise NGMS strategy we present here is comparable with
the approach taken in the genomics field to whole-exome
sequencing analysis. In the current-day situation, whole-
exome analysis is mostly initiated with targeted evaluation of a
a1 a2
Xanthine
Urate
b
N1-Methyl-2/4-pyridone-5-carboxamide
5-Hydroxyisourate
c
d e
Fig. 3 Next-generation metabolic screening (NGMS) results in
xanthinuria type II. Panels b–e, show the feature intensity distribution
in 26 control plasma samples (X-axis represents feature peak area in
arbitrary units), and should be interpreted as described in Fig. 1. Red
patient values. a xanthine dehydrogenase (XDH) (a1) and aldehyde ox-
idase (AO) function (a2). bXanthine, m/z 151.02624 ([M −H] − adduct),
retention time (RT) 2.02, is significantly increased in the patient sample
(fold change 7.2). c 5-Hydroxyisourate, m/z 183.01634 ([M − H]−
adduct), RT 1.47, is significantly decreased in the patient sample (fold
change −15.4). d Urate, m/z 167.02137 ([M − H]− adduct), RT 1.49, is
virtually absent in the patient sample (fold change −810.2). b–d represent
perturbations resulting from defective xanthine dehydrogenase (XDH)
function (see pathway in a1). eN-1-methyl-4/2-pyridone-5-carboxamide,
m/z 153.0659 ([M +H] + adduct), RT 2.95, is virtually absent in the pa-
tient sample (fold change −232.4) due to defective AO function (see
pathway in a2), and results are therefore indicative of type II
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disease-related selection of genes, which can subsequently
be expanded to opening all exome data. This strategy has
proven its effectiveness in clinical diagnostics and in the iden-
tification of novel disease-causing genes (Mendes et al. 2017;
Miller et al. 2015). An ideal workflow would be to perform
genomics and metabolomics analysis concurrently, with the
goal of providing a functional context to interpret genetic vari-
ants of uncertain significance. Previous studies have been per-
formed showing the complementary nature of genomic and
metabolomic analyses for interpreting genetic variants (Rhee
et al. 2016; Guo et al. 2015; Long et al. 2017; Pappan et al.
2017). Combining genomics and metabolomics data has also
led to the discovery of diagnostic biomarkers or diagnostic-
biomarker fingerprints for genetic diseases (Dunn 1961;
Sumner et al. 2007; Wishart et al. 2007; Dunn et al 2011; de
Ligt et al. 2012; Gilissen et al. 2012; Guo et al. 2015; Miller
et al 2015; Abela et al. 2016; Rhee et al. 2016; van Karnebeek
et al. 2016; Abela et al. 2017; Kanehisa et al. 2017; Long et al.
2017; Pappan et al. 2017; Vaclavik et al. 2017). Additionally,
further integration of metabolomics and genomics with
phenomics data, making use of the specialized expertise of clini-
cians and laboratory specialists, has shown great potential, as
described by Tarailo-Graovac et al. (2016).
A first proof of the diagnostic power of our NGMS setup in
combination with genomics data was obtained through the dis-
covery of a novel IEM: NANS deficiency (van Karnebeek et al.
2016). As a second example, in this article, we present a variant
of uncertain significance in the gene associated with Canavan
disease (ASPA), which according to our NGMS data suggest
not to be disease-causing in the homozygous form. During prep-
aration of this manuscript, the ASPA Ile170Thr variant was re-
ported in a study that correlated residual aspartoacylase enzyme
activity to patient geno- and phenotype (Mendes et al. 2017). In
their study, the Ile170Thr variant was reported to be homozygous
Histidine “Imidazole lactate”
Histidine
Histidine
Transaminase
Histidine
Ammonia Lyase
Urocanate
Imidazole
pyruvate
Imidazole
lactate
c
d e
N-Acetyl-
aspartic acid
Asparto-
acylase
Aspartic
acid
a
b
N-Acetylasparticacid
Fig. 4 Next-generation metabolic screening (NGMS) for Canavan dis-
ease and histidinemia. In panels b, d, and e, boxplots show the feature-
intensity distribution in control plasma samples (N = 27, N = 29, and N =
29, respectively; the X-axis represents feature peak area in arbitrary units)
and should be interpreted as described in Fig. 1. Red patient values. a N-
acetylaspartic acid metabolism: in Canavan disease, the function of
aspartoacylase is deficient. b N-acetylaspartic acid [M +Na] + feature
(m/z 198.03723, retention time (RT) 1.15): significantly increased in
plasma (red circle, fold change 36.5). In a patient with a variant of
uncertain significance (VUS) in the Canavan-associated ASPA gene (red
triangle), this feature was not significantly altered (fold change 4.6). c
Histidine metabolism: in histidinemia, the function of histidine ammonia
lyase is deficient. d Histidine, m/z 154.06247 ([M − H] − adduct), RT
0.60, is significantly increased in the patient sample (fold change 6.9). eA
feature with m/z 157.06074 and RT 0.71: significantly increased in the
patient sample (fold change 13.6); this feature putatively represents the
[M +H] + adduct of imidazole lactic acid, which is derived from metab-
olism of accumulating histidine, as depicted in c
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in another patient with a mild phenotype not typical for Canavan
disease. In an in vitro enzyme-activity assay in transfected
HEK239 cells, a relatively high residual activity was found for
the Ile170Thr variant. The conclusion of the authors was there-
fore that Ile170Thr is a rare variant of uncertain clinical signifi-
cance. Our NGMS results in plasma now further support these
findings. In all likelihood, the signs and symptoms of our patient
must have another underlying cause. We cannot exclude, how-
ever, that the ASPA Ile170Thr variant in combination with a
nonsense variant would cause a classical Canavan phenotype.
Even though the preceding data perfectly illustrate the prom-
ises that NGMS holds for the field of IEM diagnostics, some
challenges encountered during the validation of our NGMS
method need to be addressed. As was described in the
BResults^ section, for four of 46 IEMs tested, diagnosis could
not be established through our standard NGMSworkflow. Two
main reasons for false-negative results could be defined. First,
somemetabolites were not recognized by the XCMS alignment
algorithm, as they were not identified in the aligned data files,
while inspection of the raw data did confirm perturbations in
their levels compared with controls. These alignment issues
arose for guanidinoacetate, argininosuccinic acid, and
dimethylglycine, which all had a short retention time of
~0.6 min, which is still considered to be in the void volume
of the UHPLC column. In general, polar metabolites, such as
amino acids and sugars, exhibit only marginal retention on
reverse-phase columns, as used in the NGMS setup described
here. However, the relatively short retention time did not appear
to be the major reason for alignment failure, as for several other
metabolites that co-eluted ~0.6 min (e.g., citrulline,
sedoheptulose, and methionine sulfoxide), the alignment pro-
cedure was correct. The fold changes of missing and correctly
aligned metabolites with a retention time of ~0.6 min were of
comparable range. The exact cause of the failure of the XCMS
algorithm for alignment of guanidinoacetate, argininosuccinic
acid, and dimethylglycine is therefore as yet unclear. In future
development of our NGMS bioinformatic pipeline, we aim to
develop an in-house feature-alignment algorithm that can be
further tested and optimized to prevent alignment errors. Also,
the application of a second column type, such as hydrophilic
liquid interaction chromatography (HILIC) (Cuykx et al. 2017),
will improve retention times for polar compounds and reduce
co-elution of these metabolites, which will allow for optimal
resolution of peaks and likely facilitate their correct alignment.
Another marker that was not detected by the alignment al-
gorithm was alloisoleucine. In the MSUD patients tested in this
study, no alloisoleucine was reported as significantly increased
in the final NGMS results. Looking retrospectively at the raw
UHPLC-QTOF-MS data, we did observe a dual peak at the
position of isoleucine (Supplemental Fig. 3). Upon analysis of
a mixture of the model compounds of alloisoleucine and iso-
leucine, a similar peak pattern was observed as for the MSUD
patients, likely confirming the presence of alloisoleucine.
However, it is clear that these stereoisomers cannot completely
be separated on the UHPLC column, and in the alignment,
these peaks are clustered, leading to a single annotation of iso-
leucine, which stands out as significantly increased compared
with controls. As other specific MSUD biomarkers were iden-
tified as significantly disrupted in the NGMS analysis (such as
2-hydroxy−3-methylbutyric acid and 2-hydroxyisocaproic ac-
id, see Table 1), the missing alloisoleucine identification did not
cause a false-negative result for MSUD.
A second cause of unsuccessful metabolite identification can
be sought in the very strict statistical selection procedure of sig-
nificantly different features between an individual patient and
controls. As >10,000 features are found in each sample, statistical
comparison of features between samples should correct for false-
positive identification due to multiple testing. To overcome this
issue, we made use of the Bonferroni correction, which is the
most stringent multiple testing correction. It divides the overall
desired P value for significance by the amount of t tests per-
formed, thereby controlling the probability that at least one t test
will give a false-positive result. Because of this strict statistical
selection, modest fold changes between patient and controls
might be missed, or high variation in MS signal intensity be-
tween control samples could lead to incorrect statistical dismissal.
We see an example of this for the patient with lysinuric protein
intolerance (on benzoate treatment). No relevant metabolite dis-
ruptions (including decreased lysine or increased orotic acid con-
centrations) were detected in the NGMS analysis in plasma. One
might speculate that in urine, significantly increased lysine, orni-
thine, and/or arginine may have been identified; however, we did
not yet apply our NGMS approach to urine samples. Upon eval-
uation of the raw NGMS data for lysine, a negative fold change
was observed. In the conventional amino acid analysis using ion-
exchange chromatography, the lysine concentration was clearly
decreased—37 µmol/L, with a lower reference limit of 81.
However, in the NGMS data-processing pipeline, the lysine-
associated feature was rejected in the statistical selection, as the
corrected P value was >0.05. With the analysis of big data, such
as our NGMS results, the challenge lies in finding the right
balance between reducing false-positive identifications while
preventing false negatives. In our strict correction procedure,
false positives are nearly excluded, but there is a risk for false
negatives for relatively mild perturbations and/or features that
show a high variation in controls. In an update of our NGMS
data-processing pipeline, we intend to evaluate the less strict
Benjamini–Hochberg false discovery rate correction (Benjamini
and Hochberg 1995). The main difference is that the Benjamini–
Hochberg procedure is designed to control the expected proportion
of false-positive discoveries in a final set of significantly disrupted
features, so with a P value of <0.5, maximally 5% of
identified features can be false positives. In our validation
study, we mainly used samples of patients who were pre-
viously diagnosed and who already received appropriate
treatment for their specific condition. This clinical management
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could alleviate the biochemical perturbations in these patients,
and one could argue that in screening samples of yet undiagnosed
patients, metabolite alterations will be more pronounced, and
strict statistical selection would therefore be less of an issue.
We will also evaluate multivariate approaches to identifying sig-
nificant metabolite aberrations (Engel et al. 2014, 2017). Our
goal in this would be to automatically map multiple metabolite
perturbations on a single, most likely perturbed, metabolic path-
way and to take information of shared pathways into account for
determining statistical probability in identification. We are cur-
rently expanding our bioinformatics pipeline to include pathway
information from KEGG (Kanehisa et al. 2017) and
ReconMap 2 (Noronha et al. 2017; Thiele et al. 2013) to realize
this next level in NGMS data processing.
We tested our NGMS methodology in a substantial set of
46 different IEMs. Due to the rare nature of this class of dis-
eases, it is impossible to directly test diagnostic efficiency of
NGMS in patient plasma for all known IEMs. However, based
on a recently published IEM database containing clinical, bio-
chemical, and phenotypic profiles of 530 known IEMs
(IEMbase; Lee et al. 2017), we made an educated estimation
of the proportion of IEMs that could hypothetically be detect-
ed by our approach. We cross-referenced the 340 metabolites
of our IEM panel to IEMbase through their HMDB IDs and
extracted the OMIM codes of their associated IEMs. Based on
this comparison, we could extrapolate the diagnostic yield of
our IEM panel metabolites and estimate that at least 205 indi-
vidual IEMs can be diagnosed by our single-platform NGMS
setup. IEMs that are not covered in the current situation in-
clude lysosomal storage disorders, congenital disorders of gly-
cosylation, disorders of steroid metabolism, disorders of
(apo)lipoprotein metabolism, porphyrias, and disorders of
copper metabolism as main disease categories. When a pa-
tient’s phenotype is suggestive for one of these diseases, con-
ventional targeted biochemical analysis should be performed
in parallel to NGMS. Additionally, lipidomics (Griffiths et al.
2011) could be applied as a complementary holistic lipid-
screening method alongside our NGMS methodology.
Finally, after a diagnosis has been made, a dedicated targeted
method may be applied to provide quantitative information on
relevant disease biomarkers for patient follow-up.
As our IEM panel strategy relies on identifying metabolites
through their unique HMDB identifier, known disease metab-
olites not yet available in HMDBmight be missed. To prevent
this issue, we set up a close collaboration with HMDB to
ensure addition of missing endogenous metabolites to
HMDB. For the subsequent step of untargeted open the me-
tabolome analysis, apart from identification based on HMDB,
we will evaluate unknown features when significantly altered
in a patient through other databases, such as Metlin or KEGG.
Significant features for which identification is not possible,
which we term Bfeatures of uncertain significance^ (FUS),
will be stored in an in-house database coupled to anonymized
patient phenotype and medication data for future reference. In
every individual patient, many FUS are found upon
untargeted analysis of significantly differing features. These
FUS may be the result of modifications of metabolites in hu-
man endogenous metabolism; however, they may also derive
from food, medication, or the intestinal microbiome, adding
an extra layer of complexity to the metabolomic profile. The
number of FUS in every plasma sample is considerable and a
major hurdle that restricts the current clinical applicability of
the open the metabolome strategy. This issue asks for concert-
ed action of the IEM field to shed further light on this. When a
FUS persists in multiple samples of an individual patient, is
present in low frequency in the FUS database, and medication
can be excluded as a source, it may be a relevant novel bio-
marker for a patient’s disease. Such apparent biomarkers can
be selected for further investigation to establish identification,
for example, through multistep fragmentation MS, by infrared
spectroscopy (Martens et al. 2017), or via orthogonal ap-
proaches such as as NMR spectroscopy. Sharing FUS experi-
ence between centers will certainly advance the field further
and guide the interpretation of untargeted metabolomics data.
In conclusion, we present a single-platform, untargeted,
high-resolution, LC-QTOF, metabolomic profiling method—
NGMS—which can be successfully applied for diagnosing a
substantial spectrum of IEMs in individual patients. Through a
dual targeted/untargeted data analysis strategy, we can achieve
swift diagnosis of known IEMs while allowing for identifica-
tion of novel biomarkers and diseases. As a third option, we
can integrate genomics and metabolomics data to facilitate
interpretation of genetic variants of uncertain significance.
Even though challenges lie ahead in optimizing our method-
ology, we are convinced that metabolomics is the way forward
for biochemical diagnostics in the field of IEMs.
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